Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Who May Qualify: - Male or female patients aged ≥18 years. - Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy. - Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression. Who Should NOT Join This Trial: - Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy. - Patients who have received HAL at any time prior to screening. Always talk to your doctor about whether this trial is right for you.